X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs FRESENIUS KABI ONCO. - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD FRESENIUS KABI ONCO. BIOCON LTD/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 71.2 22.1 321.6% View Chart
P/BV x 6.7 3.1 215.1% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 BIOCON LTD   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
FRESENIUS KABI ONCO.
Mar-13
BIOCON LTD/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,162176 660.2%   
Low Rs48379 614.6%   
Sales per share (Unadj.) Rs194.637.7 516.3%  
Earnings per share (Unadj.) Rs34.45.1 675.5%  
Cash flow per share (Unadj.) Rs48.36.7 717.9%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.10-  
Book value per share (Unadj.) Rs241.942.5 568.5%  
Shares outstanding (eoy) m200.00158.23 126.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.23.4 125.2%   
Avg P/E ratio x23.925.0 95.7%  
P/CF ratio (eoy) x17.018.9 90.0%  
Price / Book Value ratio x3.43.0 113.6%  
Dividend payout %2.90-   
Avg Mkt Cap Rs m164,44020,135 816.7%   
No. of employees `0009.21.2 801.6%   
Total wages/salary Rs m7,470703 1,062.3%   
Avg. sales/employee Rs Th4,213.95,176.2 81.4%   
Avg. wages/employee Rs Th809.0610.4 132.5%   
Avg. net profit/employee Rs Th745.2699.6 106.5%   
INCOME DATA
Net Sales Rs m38,9115,963 652.5%  
Other income Rs m1,57118 8,727.8%   
Total revenues Rs m40,4825,981 676.8%   
Gross profit Rs m9,7951,430 684.9%  
Depreciation Rs m2,772258 1,074.8%   
Interest Rs m260-26 -1,000.0%   
Profit before tax Rs m8,3341,216 685.2%   
Minority Interest Rs m1630-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m1,616342 472.2%   
Profit after tax Rs m6,881806 853.8%  
Gross profit margin %25.224.0 105.0%  
Effective tax rate %19.428.1 68.9%   
Net profit margin %17.713.5 130.8%  
BALANCE SHEET DATA
Current assets Rs m40,4775,102 793.4%   
Current liabilities Rs m16,7832,385 703.6%   
Net working cap to sales %60.945.6 133.7%  
Current ratio x2.42.1 112.8%  
Inventory Days Days60150 39.7%  
Debtors Days Days83113 73.1%  
Net fixed assets Rs m45,0735,148 875.5%   
Share capital Rs m1,000158 632.1%   
"Free" reserves Rs m47,3776,556 722.7%   
Net worth Rs m48,3776,732 718.6%   
Long term debt Rs m21,082952 2,214.0%   
Total assets Rs m93,94210,388 904.3%  
Interest coverage x33.1-45.8 -72.2%   
Debt to equity ratio x0.40.1 308.1%  
Sales to assets ratio x0.40.6 72.2%   
Return on assets %7.67.5 101.2%  
Return on equity %14.212.0 118.8%  
Return on capital %12.614.6 86.3%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m12,9885,298 245.2%   
Fx outflow Rs m7,8991,772 445.7%   
Net fx Rs m5,0893,525 144.4%   
CASH FLOW
From Operations Rs m6,4001,274 502.3%  
From Investments Rs m-4,985-1,204 414.0%  
From Financial Activity Rs m-1,775-196 905.2%  
Net Cashflow Rs m-473-126 374.5%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 81.0 25.4%  
Indian inst/Mut Fund % 8.4 0.3 2,800.0%  
FIIs % 10.7 9.6 111.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 9.1 218.7%  
Shareholders   109,995 42,599 258.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   ALEMBIC PHARMA  STRIDES SHASUN LTD  J.B.CHEMICALS  ASTRAZENECA PHARMA  DIVIS LABORATORIES  

Compare BIOCON LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Green; IT & Healthcare Stocks Gain(09:30 am)

Asian stock markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.16% while the Hang Seng is down 0.49%. The Nikkei 225 is trading down by 0.43%.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Jan 17, 2018 11:33 AM

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD - DIVIS LABORATORIES COMPARISON

COMPARE BIOCON LTD WITH

MARKET STATS